Fortress Biotech (FBIO) Expected to Announce Earnings on Wednesday

Fortress Biotech (NASDAQ:FBIO) is expected to be announcing its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $11.62 million for the quarter.

Fortress Biotech (NASDAQ:FBIO) last announced its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.53. The company had revenue of $15.12 million for the quarter, compared to the consensus estimate of $16.30 million. On average, analysts expect Fortress Biotech to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fortress Biotech Stock Performance

Shares of FBIO opened at $1.76 on Tuesday. The firm has a market cap of $52.04 million, a P/E ratio of -0.58 and a beta of 1.85. Fortress Biotech has a 52 week low of $1.33 and a 52 week high of $2.89. The firm’s 50-day simple moving average is $1.63 and its 200 day simple moving average is $1.76.

Wall Street Analyst Weigh In

Separately, Roth Mkm reaffirmed a “buy” rating and issued a $16.00 target price (up previously from $15.00) on shares of Fortress Biotech in a research report on Tuesday, March 11th.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.